TRCT
CRXTW

Tower Research Capital (TRC)’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-91
Closed – – 6940
2022
Q3 		$0 Hold
91
– – ﹤0.01% 6909
2022
Q2 		$0 Hold
91
– – ﹤0.01% 6982
2022
Q1 		$0 Hold
91
– – ﹤0.01% 7055
2021
Q4 		$0 Hold
91
– – ﹤0.01% 6946
2021
Q3 		$0 Buy
+91
New +$69 ﹤0.01% 6473

Tower Research Capital (TRC)'s CRXTW Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q4 2022, closing a stake of 91 shares.

Tower Research Capital (TRC) first reported a position in CRXTW in Q3 2021 and held it in 5 quarters. The position peaked at $0 in Q3 2022. 0 funds tracked by Wall St. Rank hold CRXTW as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 91 Clarus Therapeutics Holdings, Inc. Warrants shares in Q4 2022.
  • Tower Research Capital (TRC) first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q3 2021 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s Clarus Therapeutics Holdings, Inc. Warrants position peaked at $0 in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.